Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
10:21am, Monday, 05'th Jan 2026
Zenas BioPharma Inc. (NASDAQ: ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
09:15am, Monday, 05'th Jan 2026
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seek
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
08:29am, Monday, 05'th Jan 2026
Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time.
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -
Zenas BioPharma (NASDAQ:ZBIO) Sets New 52-Week High – Here’s What Happened
04:37am, Thursday, 25'th Dec 2025
Shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) hit a new 52-week high on Tuesday. The stock traded as high as $42.99 and last traded at $42.33, with a volume of 727990 shares trading
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 19'th Dec 2025
WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
03:54am, Tuesday, 16'th Dec 2025
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight brokerages that are currently covering the firm, MarketBeat reports. One researc
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercia
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating
04:18am, Monday, 15'th Dec 2025
Zenas BioPharma is rated a buy ahead of the pivotal INDIGO Phase 3 trial readout for obexelimab in IgG4-RD, expected by year-end. ZBIO's strong balance sheet, with $301.6M in cash and runway into late
Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO
04:20am, Thursday, 11'th Dec 2025
Federated Hermes Inc. increased its stake in Zenas BioPharma, Inc. (NASDAQ: ZBIO) by 60.8% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor ow
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
09:14am, Thursday, 20'th Nov 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation see
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:05am, Wednesday, 12'th Nov 2025
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
07:05am, Tuesday, 11'th Nov 2025
WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
01:34pm, Tuesday, 28'th Oct 2025
A pivotal clinical development has sent Zenas BioPharma NASDAQ: ZBIO shares climbing higher, reshaping the company's investment profile overnight. On Oct. 27, 2025, Zenas BioPharma's stock price climb
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
07:05am, Monday, 27'th Oct 2025
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -
